ADMA News and Press, ADMA Biologics Inc From 10/31/22

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J., BOCA RATON, Fla. and Myrtle Beach, SC. , Oct. 31, 2022 (GLOBE NEW...

Summary Adma Biologics saw its share price reach an all-time low of $1.10 in October 2021. The company is engaged in operating plasma donor centers and marketing and selling plasma derive therapies. The company's revenues were up >90% year-on-year in Q222, but net loss stil...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter. The new National Biotechnology and Biomanufacturing I...

Shares of ADMA Biologics Inc (NASDAQ:ADMA) traded at a new 52-week high today of $2.80. So far today approximately 139,000 shares have been exchanged, as compared to an average 30-day volume of 2.2 million shares. ADMA Biologics Inc share prices have moved between a 52-week high of $2.80...

Investing in Meme Penny Stocks Right Now, 3 Tips When it comes to investing in penny stocks, it can be argued that it is worth it, as there is the potential to make a large return on investment. However, it is also risky, as penny stocks are more volatile than other stocks and can l...

ADMA Biologics recently reported their Q2 earnings with impressive revenue growth and improved margins. The company is on clear a path toward profitability. The market seems to have identified the opportunity that ADMA offers and has supported the share after hitting its low in Octobe...

Shares of ADMA Biologics Inc (NASDAQ:ADMA) traded today at $2.64, eclipsing its 52-week high. Approximately 101,000 shares have changed hands today, as compared to an average 30-day volume of 2.1 million shares. ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company ded...

ADMA Biologics (NASDAQ: ADMA) , typically one of the more under-the-radar coronavirus stocks, was very much on the radar of many investors on Thursday. The company's shares popped by over 5% on an otherwise generally flat day for stocks in general, thanks to an estimates-beating sec...

Adma Biologics ( NASDAQ: ADMA ) stock rose ~10% after Q2 revenue grew ~90% year over year. Total revenues were $33.9M, compared to $17.83M in Q2 2021. The company said the increase was due to a favorable product mix, as it continues to expand its customer base for im...

Shares of ADMA Biologics Inc (NASDAQ:ADMA) traded today at $2.48, eclipsing its 52-week high. So far today approximately 253,000 shares have been exchanged, as compared to an average 30-day volume of 1.8 million shares. ADMA Biologics Inc is an end-to-end commercial biopharmaceutical com...